Endologix

Endologix, Inc. is a developer and manufacturer of minimally invasive treatments for aortic disorders. We have over 850 employees and listed on NASDAQ (ELGX). Since launching in the U.S. in 2005, Endologix has experienced average annual growth of 60%+ and was the top performing med tech stock in 2009. The Company's Powerlink® System is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. More than 2 million people in the U.S. have AAA, with 200,000 new cases diagnosed every year. If left untreated, AAAs become increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the U.S.

Type

Public

Irvine, US

Size (employees)

782 (est)+27%

Website

endologix.com

Endologix is headquartered in Irvine, US

Endologix Office Locations

Endologix has offices in Irvine and Rosmalen

Irvine, US (HQ)

2 Musick

Rosmalen, NL

40 Burgemeester Burgerslaan

Endologix Data and Metrics

Endologix Financial Metrics

Endologix's revenue was reported to be $192.9 m in FY, 2016 which is a 26% increase from the previous period.

Summary

USD

Endologix's current market capitalization is $417.4 m.

Income Statement

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	132.3 m	147.6 m	153.6 m	192.9 m
Revenue growth, %		12%	4%	26%
Cost of goods sold		41.8 m	51.8 m	69.1 m
Gross profit	99.5 m	105.8 m	101.8 m	123.8 m
Gross profit Margin, %	75%	72%	66%	64%
Operating expense total	109.9 m	134.9 m	154.7 m	218.9 m
EBIT	(10.4 m)	(29.1 m)	(52.9 m)	(95.1 m)
EBIT margin, %	(8%)	(20%)	(34%)	(49%)
Interest expense	321 k	5.7 m	7.5 m	15.8 m
Interest income	50 k	245 k	175 k	228 k
Income tax expense	10 k	62 k	9.3 m	(498 k)
Net Income	(16.1 m)	(32.4 m)	(50.4 m)	(154.7 m)

Balance Sheet

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	95.2 m	26.8 m	124.6 m	26.1 m
Accounts Receivable	310 k	498 k	375 k	1.8 m
Inventories	19.6 m	31.3 m	27.9 m	41.2 m
Current Assets	173.6 m	147.8 m	237.5 m	129.8 m
PP&E	7.3 m	25.7 m	23.4 m	23.3 m
Goodwill	29.1 m	28.9 m	28.7 m	120.7 m
Total Assets	256.2 m	248.2 m	335.8 m	359.7 m
Accounts Payable	6.3 m	11 m	17.5 m	13.2 m
Current Liabilities	67.3 m	29.6 m	50.9 m	44.9 m
Additional Paid-in Capital	321.8 m	372.6 m	404.5 m	567.8 m
Retained Earnings	(216.1 m)	(248.5 m)	(298.9 m)	(453.6 m)
Total Equity			103.3 m	112.8 m
Financial Leverage			3.3 x	3.2 x

Cash Flow

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income		(32.4 m)	(50.4 m)	(154.7 m)
Depreciation and Amortization		3.3 m	5.9 m	9.1 m
Inventories		(12 m)	3.5 m	3.5 m
Accounts Payable		2.7 m	8.3 m	(5.2 m)
Cash From Operating Activities	50 m	(26.3 m)	(31.1 m)	(74.8 m)
Purchases of PP&E		(13.5 m)	(4.2 m)	(2.8 m)
Cash From Investing Activities		(43.3 m)	2.9 m	(28.5 m)
Cash From Financing Activities		2.1 m	126.7 m	5.3 m
Interest Paid		2 m	2 m	6.3 m
Income Taxes Paid		258 k	124 k	208 k